Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Mytide Therapeutics is raising $7,067,713.00 in new funding. Sources indicate as part of senior management President, Dale Thomas played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Mytide Therapeutics
mytide is a groundbreaking technology startup focused on accelerating peptide therapeutics R&D. We are a multi-disciplinary team of engineers, biochemists, and computer scientists who have created the first company to take a technologically advanced approach to solving long-standing challenges in both peptide synthesis and purification. mytides fully automated peptide manufacturing technology, coupled with predictive analytics and machine learning, is challenging decades-old paradigms to enable cost-efficient research and development, therapeutic manufacturing and therapeutic discovery. Our aim is to accelerate the discovery and development of life-saving peptide therapeutics for serious conditions ranging from metabolic conditions to cancer to inflammatory disorders to infectious diseases.

To learn more about Mytide Therapeutics, visit http://www.mytide.io/

Contact:
Dale Thomas, President
207-659-4206
dale@mytide.io
https://www.linkedin.com/in/dale-thomas-4b318564/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved